OPKO Health, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
OPKO Health, Inc. (OPK) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$16.47 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-28
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was -$8.31M.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$8.16M.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was -$3.78M, a 201.21% decline year-over-year.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$420.00K, a 101.01% decline year-over-year.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$47.84M, a 198.27% decline from fiscal 2024.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $48.68M.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$5.48M.
- OPKO Health, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$91.11M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.31M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | -$16.47M 10-Q/A · filed 2026-08-28 | -$20.25M derived: sum of 3 quarters · filed 2026-08-28 | -$20.67M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2026-03-31 | -$8.16M 10-Q/A · filed 2026-08-28 | -$11.94M derived: sum of 2 quarters · filed 2026-08-28 | -$12.36M derived: sum of 3 quarters · filed 2026-08-28 | -$36.60M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-12-31 | -$3.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.20M derived: sum of 2 quarters · filed 2026-02-26 | -$28.44M derived: sum of 3 quarters · filed 2026-08-28 | -$47.84M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$420.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | -$24.67M derived: sum of 2 quarters · filed 2026-08-28 | -$44.06M 10-Q · filed 2025-10-29 | -$40.33M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-06-30 | -$24.25M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | -$43.64M 10-Q/A · filed 2026-08-28 | -$39.91M derived: sum of 3 quarters · filed 2026-08-28 | $1.60M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2025-03-31 | -$19.40M 10-Q/A · filed 2026-08-28 | -$15.67M derived: sum of 2 quarters · filed 2026-08-28 | $25.85M derived: sum of 3 quarters · filed 2026-08-28 | $30.33M derived: sum of 4 quarters · filed 2026-08-28 | ||
| 2024-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $45.24M derived: sum of 2 quarters · filed 2026-02-26 | $49.73M derived: sum of 3 quarters · filed 2026-02-26 | $48.68M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $41.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $46.00M derived: sum of 2 quarters · filed 2025-10-29 | $44.95M 10-Q · filed 2025-10-29 | -$139.08M 10-Q · filed 2024-11-07 | $29.38M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $4.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $3.44M 10-Q · filed 2025-07-31 | -$12.13M derived: sum of 3 quarters · filed 2026-02-26 | -$7.11M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | -$1.05M 10-Q · filed 2025-05-01 | -$16.62M derived: sum of 2 quarters · filed 2026-02-26 | -$11.60M derived: sum of 3 quarters · filed 2026-02-26 | -$16.07M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2023-12-31 | -$15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$10.55M derived: sum of 2 quarters · filed 2026-02-26 | -$15.02M derived: sum of 3 quarters · filed 2026-02-26 | -$5.48M 10-K · filed 2026-02-26 | -$5.35M 10-K · filed 2024-03-01 | |
| 2023-09-30 | $5.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $550.00K derived: sum of 2 quarters · filed 2024-11-07 | $10.10M 10-Q · filed 2024-11-07 | -$1.37M 10-Q · filed 2023-11-06 | $1.62M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$4.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $5.07M 10-Q · filed 2024-08-07 | -$3.41M derived: sum of 3 quarters · filed 2025-03-03 | -$16.06M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $9.55M 10-Q · filed 2024-05-07 | $1.07M derived: sum of 2 quarters · filed 2025-03-03 | -$11.59M derived: sum of 3 quarters · filed 2025-03-03 | |||
| 2022-12-31 | -$8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$21.13M derived: sum of 2 quarters · filed 2025-03-03 | -$91.11M 10-K · filed 2025-03-03 | -$90.78M 10-K · filed 2024-03-01 | ||
| 2022-09-30 | -$12.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$82.63M 10-Q · filed 2023-11-06 | ||||
| 2022-06-30 | -$69.98M 10-Q · filed 2023-08-03 | |||||
| 2021-12-31 | -$33.72M 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |